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RNA editing is an alteration in the primary nucleotide sequences resulting from a chemical
change in the base. RNA editing is observed in eukaryotic mRNA, transfer RNA, ribosomal
RNA, and non-coding RNAs (ncRNA). The most common RNA editing in the mammalian
central nervous system is a base modiﬁcation, where the adenosine residue is base-
modiﬁed to inosine (A to I). Studies from ADAR (adenosine deaminase that act on RNA)
mutants in Caenorhabditis elegans, Drosophila, and mice clearly show that the RNA editing
process is an absolute requirement for nervous systemhomeostasis and normal physiology
of the animal. Understanding the mechanisms of editing and ﬁndings of edited substrates
has provided a better knowledge of the phenotype due to defective and hyperactive RNA
editing. A to I RNA editing is catalyzed by a family of enzymes knows as ADARs. ADARs
modify duplex RNAs and editing of duplex RNAs formed by ncRNAs can impact RNA
functions, leading to an altered regulatory gene network. Such altered functions by A
to I editing is observed in mRNAs, microRNAs (miRNA) but other editing of small and
long ncRNAs (lncRNAs) has yet to be identiﬁed. Thus, ncRNA and RNA editing may
provide key links between neural development, nervous system function, and neurological
diseases. This review includes a summary of seminal ﬁndings regarding the impact of
ncRNAs on biological and pathological processes, which may be further modiﬁed by
RNA editing. NcRNAs are non-translated RNAs classiﬁed by size and function. Known
ncRNAs likemiRNAs, smallRNAs (smRNAs), PIWI-interactingRNAs (piRNAs), and lncRNAs
play important roles in splicing, DNA methylation, imprinting, and RNA interference. Of
note, miRNAs are involved in development and function of the nervous system that is
heavily dependent on both RNA editing and the intricate spatiotemporal expression of
ncRNAs. This review focuses on the impact of dysregulated A to I editing and ncRNAs in
neurodegeneration.
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INTRODUCTION
Environmental signals provoke changes in gene expression in
a mechanism that includes epigenetic-mediated gene regulation
(Kubota et al., 2012; Miyake et al., 2012). Epigenetic regulation of
gene expression has key roles in development, stress responses, and
plasticity of the central nervous system (CNS). Epigenetic mod-
iﬁcations include RNA editing and chromatin remodeling (i.e.,
histone modiﬁcations), and DNA methylation (Zhou et al., 2008;
Luco and Misteli, 2011; Luco et al., 2011). Increasing evidence
demonstrates that long non-coding RNAs (lncRNAs) are directed
to the sites of action in the genome, suggesting that lncRNAs may
be involved in regulation of methylation and chromatic remod-
eling (Luco and Misteli, 2011; Luco et al., 2011). In the CNS,
dysregulation of these critical epigenetic processes leads to the
pathogenesis of a broad range of neurological and psychiatric
diseases (Mattick and Gagen, 2001; Clark, 2007).
Numerous classes of regulatory non-coding RNA (ncRNA)
molecules contribute to the intricate biological system organiza-
tion and gene regulatory networks that collectively allow normal
functioning of the CNS. Dysregulation of these complex gene
regulatory networks plays a signiﬁcant role in the pathogenesis
of common neurodegenerative disease such as Alzheimer’s dis-
ease (AD), Parkinson disease (PD), Huntington disease (HD),
and amyotrophic lateral sclerosis (ALS; Akbarian et al., 1995b;
Hideyama et al., 2012). In eukaryotes, a unifying theme in all of
these genetic diseases is alterations in RNA regulation at multi-
ple levels, including transcriptional changes, RNA editing (Burns
et al., 1997; Emeson and Singh, 2001; Bass, 2002; Blow et al., 2006;
Beal et al., 2007; Barraud and Allain, 2012), post-transcriptional
gene silencing (Mette et al., 2000; Pal-Bhadra et al., 2002; Matzke
et al., 2007; Carthew and Sontheimer, 2009; Ghildiyal and Zamore,
2009), X chromosome dosage compensation (Yang and Kuroda,
2007; Kanduri et al., 2009; Fedoriw et al., 2012), germ cell repro-
gramming (Migicovsky andKovalchuk, 2011; Guibert et al., 2012),
and para-mutation (Chandler, 2007; Cuzin et al., 2008; Figure 1).
Non-coding RNAs either receive or transmit information (Salta
and De Strooper, 2012), which is often achieved by duplex struc-
tures formed by base pairing with complementary sequences of
RNA and DNA; these duplexes can be in the form of either
RNA:RNA or RNA:DNA complexes (Mattick, 2003; Mattick and
Makunin, 2005). RNA-induced silencing complexes (RISC) or
RNA editing by ADAR (adenosine deaminase that act on RNA)
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FIGURE 1 | Diagram showing the broad impact of dysregulated ADARs in altering A to I editing, producing defective RNAs and altering gene
expression in neurodegeneration.
enzymes recognizes these duplex structures and process them by
different mechanisms (Simpson and Emeson, 1996; Bass, 2002;
Heale et al., 2009). Intersection of RNA editing in the RNA inter-
ference process is observed in both plants and animals (Luciano
et al., 2004; Blow et al., 2006; Nishikura, 2006; Heale et al., 2009).
Editing is induced by a variety of small ncRNAs such as endoge-
nous small interfering RNAs (siRNAs), PIWI-interacting RNAs
(piRNAs), and short transcripts that sit adjacent to promoter (i.e.,
promoter-associatedRNAs;Han et al., 2007) and transcription ini-
tiation RNAs (Mehler, 2008). Furthermore, targeted RNA editing
in the 3′ untranslated region (UTR) can affect stability, translation,
or localization of mRNAs (Kuersten and Goodwin, 2003; Sie and
Kuchka, 2011; Irimia et al., 2012). Taken together, these ﬁndings
support the hypothesis that there is cross talk between RNA edit-
ing and the silencing machinery (Scadden and Smith, 2001; Blow
et al., 2006; Nishikura, 2006; Ohman, 2007; Heale et al., 2009).
DYSREGULATED A–I EDITING IN NEURODEGENERATION
Adenosine (A) to inosine (I) conversion in mRNA transcripts (A
to I RNA editing) is catalyzed by a family of enzymes known as
ADARs. Since inosine has the same base pairing properties as
guanosine (G), the transcription and translational machinery rec-
ognizes I as a G. Hence, a silent mutation is created at the level of
mRNA. In general, A to I editing most frequently targets repeti-
tive RNA sequences located within the introns and 5′ and 3′ UTR
to alter both sequence and structure of RNA. A to I editing is
widespread and essential for normal life and development (Valente
and Nishikura, 2005; Horsch et al., 2011). The ADAR gene family
andA-to-I RNA editing deregulation, which results in uncorrected
forms of hyper- or hypoediting, has been implicated in a spectrum
of neurodevelopmental, neurodegenerative, and neuropsychiatric
disorders, strongly suggesting diverse roles in post-transcriptional
gene regulation (Valente and Nishikura, 2005).
A to I RNA editing of targeted substrates in the nervous sys-
tem can alter functional properties of proteins, silence constitutive
activity, and modulate RNA translation, localization, and stability
(Paul and Bass, 1998; Bass, 2002). In addition to changing codons
in mRNA,A to I editing also has the capacity to modulate splicing
sites, small nucleolar RNA (sno-RNA) precursors, endogenous
antisense RNAs, microRNA (miRNA) target diversity, miRNA
and ncRNA processing, and ribonucleoprotein complex targets
(Rueter et al., 1999; Bass, 2002; Levanon et al., 2004; Blow et al.,
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2006; Kawahara et al., 2006; Kishore and Stamm, 2006; Yang et al.,
2006; Heale et al., 2009). ADAR involvement in chromatin modi-
ﬁcation and possibly in genomic imprinting and X-chromosome
inactivation has been proposed, indicating that there is interplay
between these processes and RNA-based silencing mechanisms
(Fernandez et al., 2005; Valente and Nishikura, 2005). However,
when edited mRNA is translated, editing alters biological prop-
erties and functions of proteins, such as ligand-gated receptors
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)
receptor (GluR-B subunit), serotonin 2C receptor, GABAA recep-
tor (alpha 3 subunit), and the potassium voltage-gated ion channel
KV1.1. It is of note that, they all play an important role in
nerve cell function (Emeson and Singh, 2001; Bass, 2002). ADAR2
activity can be modulated by sequestration in the nucleolus and
nucleolus-nucleoplasm shufﬂing (Desterro et al., 2003; Sansam
et al., 2003) and ADAR mRNA itself is subject to self-editing,
known as auto-editing, which restricts its function in the adult
Drosophila and mice (Rueter et al., 1999; Keegan et al., 2005;
Feng et al., 2006).
InmammalsADARs are differentially expressedduring organo-
genesis (Paupard et al., 2000; Jacobs et al., 2009). ADAR3 is
restricted to the brain, whereas ADAR2 and ADAR1 are ubiq-
uitously expressed but preferentially expressed in the CNS (Bass,
2002). During progressive stages of nervous system maturation,
RNA editing also displays complex and dynamic proﬁles of sub-
cellular localization and spatiotemporal expression (Bernard et al.,
1999; Paupard et al., 2000; Sansam et al., 2003; Jacobs et al., 2009).
Furthermore, both the behavioral state and genetic background
can modify RNA editing (Englander et al., 2005). Changing
environmental signals including inﬂammation and feedback reg-
ulation alsomodiﬁes the activity andmolecular proﬁles of ADARs
(Bass, 2002; Yang et al., 2003; Valente and Nishikura, 2005). The
potential central roles of RNA editing in brain evolution as well
as gene–environmental interactions during nervous system neural
maturation comes from studies showing environmentally respon-
sive forms of ADARs. Speciﬁcally, the p150 long cytoplasmic
isoform of ADAR1, which selectively targets endogenous anti-
sense RNA pathways, is interferon-inducible, and ADAR3 exhibits
selective regional, developmental, and mature nervous system
expression. Taken together, these data identify unique modu-
latory roles and substrate speciﬁcity for ADARs (Melcher et al.,
1996; Chen et al., 2000). ADAR2 has been found to contain inos-
itol hexaphosphate (IP6) buried within its enzyme core (Macbeth
et al., 2005). Moreover, amino acids that coordinate IP6 in ADAR2
are also conserved in adenosine deaminases that act on transfer
RNAs (ADATs), and IP6 is required for ADAT activity (Macbeth
et al., 2005), thereby linking ADAR2 to cell signaling pathways.
Multiple isoforms of ADAR1 and ADAR2 exists in the cell
(Bass, 2002). ADAR1 displays preferential tissue-speciﬁc promoter
utilization, whereas ADAR2 exists as multiple spliced isoforms
generated by alternative splicing, which results in expression of a
broad array of protein species with unique enzymatic properties
and remarkable molecular diversity (George et al., 2005; Kawa-
hara et al., 2005). ADARs are normally found as functional dimers
that can either homo or hetero dimerize with their own isoforms
(Chilibeck et al., 2006; Poulsen et al., 2006; Valente and Nishikura,
2007). However, dimerization of ADAR3 requires additional CNS
environmental cues (Cho et al., 2003). Different ADARs can also
edit multiple different sites on the same RNA species, resulting in
diverse functional outcomes (Valente and Nishikura, 2005). Stud-
ieswith transgenicmouse embryos that are deﬁcient in bothADAR
and ADARB1 activity revealed that deﬁciency of ADARB1 leads
to accumulation of speciﬁc miRNAs and corresponding targets,
thereby suggesting an important role for ADARs in miRNA bio-
genesis (Luciano et al., 2004; Yang et al., 2006; Ohman, 2007; Heale
et al., 2009; Alon et al., 2012; Vesely et al., 2012). Furthermore
ADARs binding alone can affect miRNA biogenesis and function
and RNA interference in the nervous system (Heale et al., 2009;
Paro et al., 2012). The biological roles of ADAR3 are particularly
interesting due to its broad substrate speciﬁcity (binding single-
stranded as well as double-stranded RNA) and localization that
is restricted to brain regions and post-mitotic neurons (Melcher
et al., 1996; Chen et al., 2000). ADAR3 can act as a dominant nega-
tive regulator for bothADAR1 andADAR2 activity in vitro, thereby
suggesting that correct expression levels of ADARs are required
for optimal editing. Furthermore, ADAR3 can form heterodimers
with bothADAR1 andADAR2, providingmechanistic insight into
the functional complexity associated with these enzymes in the
brain (Chen et al., 2000).
A to I editing occurs more frequently in human transcripts
than that was previously hypothesized. The majority of edit-
ing is now known to be in the Alu repeats, which are found in
introns, intergenic transcripts, and UTRs and are believed to form
duplex structures with ncRNAs (Athanasiadis et al., 2004; Kim
et al., 2004b; Levanon et al., 2004; Blow et al., 2006). The most
abundantly edited human transcripts are predominantly conﬁned
to the primate-speciﬁc Alu repeats, which are found in thousands
of genes (Neeman et al., 2006; Chen and Carmichael, 2008; Chen
et al., 2008). Interestingly, the editing levels in mouse and humans
differ due in part to a higher divergence of mouse small inter-
spersed nuclear elements (SINE) repeats and primate-speciﬁc Alu
repeats (Alon et al., 2012; Vesely et al., 2012). However, two recent
studies that estimated the total level of editing in the mouse have
found that this is not the case (Kim et al., 2004a; Eisenberg et al.,
2005). It is important to note that other mammals have a sim-
ilar number of different SINEs but display lower editing levels
as compared to humans (Morse et al., 2002;Waterston et al., 2002;
Mattick, 2003; Kim et al., 2004a; Eisenberg et al., 2005;Mattick and
Makunin, 2005; Matzke et al., 2007; Mehler, 2008; Ghildiyal and
Zamore, 2009). For example, structured mRNAs or mRNAs with
edited 3′ UTRs interact with P54nrb complexes and are retained
in the nucleus (Chen and Carmichael, 2008). In mouse, CAT2
transcribed nuclear RNA (CTN-RNA), whose 3′ UTR is edited,
is localized to paraspeckles (Prasanth et al., 2005). Studies uti-
lizing eukaryotic mutants show that A to I RNA editing is an
absolute requirement for normal functioning of the nervous sys-
tem (Reenan, 2001; Tonkin et al., 2002; Wang et al., 2004a). Not
surprisingly, deregulation of RNA editing results in dysregulation
of the nervous system (Kwak and Kawahara, 2005; Valente and
Nishikura, 2005). Abnormal RNA editing has been implicated
in epilepsy, schizophrenia, depression, suicide, prion-induced
neurodegeneration, autosomal dominant episodic ataxia type I,
PraderWilli syndrome (PWS),ALS,AD, andHD (Niswender et al.,
1999; Sodhi et al., 2001; Gurevich et al., 2002; Iwamoto and Kato,
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2003; Englander et al., 2005; Iwamoto et al., 2005; Kwak andKawa-
hara, 2005; Valente and Nishikura, 2005; Kishore and Stamm,
2006; Doe et al., 2009; Morabito et al., 2010; Singh et al., 2011;
Kiesel et al., 2012).
Brain region-speciﬁc changes at the Q/R editing site of the
GluR-B transcript have been described in both AD and HD
(Akbarian et al., 1995a,b; Wright and Vissel, 2012). The pathol-
ogy of sporadic ALS, a progressive neurodegenerative disease of
the motor neurons, is due to glutamate excito-toxicity, where
increased glutamate levels activate glutamate-gated ion channels
that results in excessive Ca++ inﬂux and neuronal death. Of note,
A to I RNA editing has been implicated in excessive Ca++ inﬂux in
ALS. Recently, it has been shown that there is a strong correlation
between increased editing in EAAT2 pre-mRNA and activation
of alternative poly A site in the motor cortex of ALS patients
(Flomen and Makoff, 2011). On the other hand, ALS patients
also have decreased editing of the Q/R site in GluR-B transcripts
of spinal motor neurons (62–100% relative to controls with 100%
editing; Kwak and Kawahara, 2005; Kwak et al., 2008). Collectively,
these observations suggest a differential deregulation of A to I edit-
ing in ALS likely leads to disturbances in the Ca++ permeability
and neuronal cell death characteristic of this disease (Akbarian
et al., 1995b).
Pharmacological studies provide a clear role for serotonin in
psychiatric disorders such as schizophrenia, depression, and anx-
iety (Kennett et al., 1997; Martin et al., 1998). Editing of the
5HT2CR mRNA is involved in the pathophysiology of psychotic
disorders. Speciﬁcally, editing regulates the efﬁcacy of hallucino-
genic and antipsychotic drugs on the 5HT2CR (Sodhi et al., 2005).
Abnormal editing of the 5HT2CR is associated with hyperpha-
gia, schizophrenia, depression, and suicide in humans (Niswender
et al., 1999; Sodhi et al., 2001; Gurevich et al., 2002; Iwamoto and
Kato, 2003; Morabito et al., 2010) and abnormal editing is also
observed in animal models of affective disorders and PWS-like
(Englander et al., 2005; Iwamoto et al., 2005; Kishore and Stamm,
2006; Doe et al., 2009; Morabito et al., 2010; Singh et al., 2011).
In animals, 5HT2CR editing is sensitive to stress and medication
as well as the genetic background and behavioral state of animals
(Iwamoto et al., 2005; Du et al., 2006; Gardiner and Du, 2006;
Hackler et al., 2006). These studies imply that animal models may
provide additional insights into the relationship between editing
of the 5HT2CR and clarify ﬁndings from postmortem brains of
patients with mental disorders. Given to the functional implica-
tions of RNA editing of substrates implicated in these diseases,
the ADAR enzymes represent novel targets to treat psychiatric
disorders.
DYSREGULATED ncRNAs IN NEURODEGENERATION
Research in the role of ncRNAs in neurodegeneration has exploded
in recent years, with several in-depth review articles available
(Mattick and Makunin, 2006; Mehler and Mattick, 2007; Dinger
et al., 2008; Mattick and Mehler, 2008; Eacker et al., 2009; Lau and
de Strooper, 2010; Sonntag, 2010; Bian and Sun, 2011; Qureshi
and Mehler, 2011, 2012; Enciu et al., 2012; Junn and Moura-
dian, 2012; Saito and Saito, 2012). In the following sections, an
overview of the impact of dysregulated ncRNAs in neurodegener-
ation is provided, with a focus on the role of RNA editing in the
pathophysiology. To date, RNA editing has only been documented
in miRNAs, but it is highly plausible that RNA editing occurs in
other ncRNA species. Thus, also included is a description of key
research ﬁndings in the role of other ncRNAs, such as snoRNAs
and lnRNAs, in neurodegenerative diseases. These ncRNA species
are ripe for research to analyze whether RNA editingmight impact
their expression and activity. Furthermore, the fact that binding
of ADARs in the absence of editing also affects miRNA biogen-
esis supports the hypothesis that ADARs can interfere with the
function of other ncRNAs.
DYSREGULATED miRNAs IN NEURODEGENERATION
The biological signiﬁcance of edited ncRNAs remains unknown.
However, the possibility of a role in RNA interference is likely
(Haramati et al., 2010; Hansen et al., 2012). RNA editing regulates
precursor miRNAs that play a role in the biogenesis and func-
tion of certain miRNAs, which are abundantly edited by ADARs
(Alon et al., 2012; Vesely et al., 2012). Several pri-miRNA are A to
I edited, which can prevent processing at either stages or modify
the targets of the ﬁnal RISC complex (Kawahara et al., 2007). The
fact that neural defects including tremors and neurodegeneration
are present in ADAR-knockout Drosophila melanogaster makes a
strong case for requirement of regulated A to I editing for normal
behavior and nervous system functioning (Palladino et al., 2000;
Keegan et al., 2005; Jepson and Reenan, 2010).
Non-coding RNAs, such as miRNAs, siRNAs, and piRNAs all
guide effector Argonaute protein to either genomic loci or target
RNAs in a sequence-speciﬁc manner (Mattick, 2003; Mattick and
Makunin, 2005; Pang et al., 2006). Development and neural cell
differentiation are regulated by brain-speciﬁc miRNAs (Haramati
et al., 2010; Hansen et al., 2012). In the adult brain at various time
points, miRNAs are known to regulate neural function and synap-
tic plasticity. Expression of miRNAs are tightly regulated during
developmental processes, cell proliferation, neuronal gene expres-
sion, brainmorphogenesis, neural cell fate, apoptosis, and stemcell
division (Mattick, 2003;Mattick andMakunin, 2005;Matzke et al.,
2007; Mehler, 2008; Ghildiyal and Zamore, 2009). The brain dis-
plays both temporal and region-speciﬁc miRNA expression, and
the most abundant miRNA expression is observed in cerebellum
and cerebral cortex (Haramati et al., 2010; Hansen et al., 2012).
Depending on where miRNAs are localized, distinct miRNAs are
also involved in memory formation (Hansen et al., 2012).
MicroRNAs can be derived from either the introns or exons
of both protein-coding and ncRNAs transcribed by RNA poly-
merase II. Processed small hairpin RNAs or double-stranded RNA
precursors give arise to miRNAs that are generally 22nt long
(Bartel, 2004). miRNAs that contain 21–23 nucleotide regulatory
sequences inhibit translation of targeted mRNA by base pair-
ing with the targeted regions in the mRNA (Pal-Bhadra et al.,
2002; Kuersten and Goodwin, 2003; Nishikura, 2006; Carthew
and Sontheimer, 2009). A number of miRNAs are associated with
neuropsychiatric diseases via silencing of targets involved in dis-
ease development. Perturbations of miRNA expression, sequence,
or target sites are all associated with numerous neuronal dis-
eases. During neuroblast differentiation, double-stranded RNA
silencing element exclusive to neuronal cells, i.e., mir-124a, dic-
tates transcriptional activation of a silencing factor (NRSF; Chen
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et al., 2012). Increased expression of mir-21 is linked to glioblas-
toma (Wang et al., 2012). DeregulatedDGCR8 expression,which is
associatedwithDiGeorge syndrome (Chen et al., 2012), is involved
in miRNA processing and in learning disability. Tourette’s syn-
drome is associated with sequence variations in mir-189, which
targets SLIT (axonal growth-controlling protein SLIT) in a mech-
anism that includes alterations in themiR-189 binding site in SLIT
and Trk-like family member1 (SLITRK-1) mRNA (Abelson et al.,
2005), a protein that is essential for neuronal growth, guidance,
and neurite branching. Deregulated mir-175 expression has been
linked to the X-linked mental retardation (MRX3), which resem-
bles an early onset PD. InWaisman syndrome, disruption of the 3′
UTR of ﬁbroblast growth factor 20 (FGF20) by a mutation alters
the recognition site of mir-433, which results in increased trans-
lation of FGF20 and is correlated with increased alpha-synuclein
expression (Dostie et al., 2003; Wang et al., 2008; Harraz et al.,
2011). All together these studies suggest that alterations inmiRNA
expression lead to dysregulated neuronal functioning.
DYSREGULATED SMALL NUCLEOLAR RNAs IN
NEURODEGENERATION
While a role for ADARs in other ncRNAs has not been reported,
ncRNAs form secondary structures that might be recognized by
ADARs. Thus, it is possible that RNA editing or ADAR binding
might alter structure and function of other ncRNAs described in
the following sections. SnoRNAs range from 60 to 300 nucleotides
in length and guide site-speciﬁc modiﬁcation of nucleotides in
target RNAs by base pairing with short regions of target RNA.
SnoRNAs can be divided into twomajor classes: the boxC\D snoR-
NAs, which guide 2′-O-ribose-methylation, and H/ACA snoRNAs
that guide pseudouridylation of target RNAs (Kiss et al., 2002,
2004). Another group known as orphan snoRNAs because of their
unknown RNA targets have been identiﬁed. Targets include ribo-
somal RNA (rRNA), small nuclear (snRNAs), and mRNAs (Pang
et al., 2006). Mammalian snoRNAs are derived from introns of
coding or non-coding genes (Meier, 2005). C\D snoRNAs are
localized to nucleolus, whereas H/ACA snoRNAs are localized to
cajal bodies. snoRNAs exhibit tissue-speciﬁc, developmental, and
imprinting-regulated expression (Rogelj and Giese, 2004).
A number of brain-speciﬁc snoRNAs have been identiﬁed in
mice including MBI-36, MBII-13, MBII-48, MBII-49, MBII-52,
MBII-78, and MBII-85 (Ding et al., 2005). These snoRNAs dis-
play brain region-speciﬁc expression and play crucial roles in
gene regulation and normal physiology. Similarly homolog of
these snoRNAs is also highly enriched in the human brain. Some
of these snoRNAs have been shown to be associated with con-
textual memory consolidation (fear conditioning; Rogelj et al.,
2003). Interestingly, snoRNA MBII-52 targets the serotonin 2C
receptor (5HT2CR) and regulates alternative splicing and edit-
ing of the 5HT2CR (Kishore and Stamm, 2006). As described
above, editing of the 5HT2CR has been implicated in depression,
anxiety, schizophrenia, and feeding regulation (Niswender et al.,
1999; Sodhi et al., 2001; Gurevich et al., 2002; Iwamoto and Kato,
2003; Hackler et al., 2006; Singh et al., 2007, 2009, 2011). Abnor-
mal MBII-52 and MBII-85 snoRNA expression (Ding et al., 2005;
Kishore and Stamm, 2006; Kishore et al., 2010) and A to I edit-
ing of the 5HT2CR editing are all implicated in PWS and obesity
(Kishore and Stamm, 2006; Kishore et al., 2010; Morabito et al.,
2010; Schellekens et al., 2012). Of note, ADAR2 is sequestered
in the nucleolus (Desterro et al., 2003; Sansam et al., 2003), and
ADAR2-mediated editing of RNA substrates in the nucleolus is
inhibited by snoRNAs (Vitali et al., 2005). Taken together, these
multiple studies suggest that a very complex RNA regulatory net-
work maintains homeostasis in the CNS (Kishore and Stamm,
2006; Kishore et al., 2010). It is unclear how editing or splicing of
the 5HT2CR contributes to pathogenesis of PWS. However, the
snoRNA SNORD-52 involvement of RNA editing and splicing
of the 5HT2CR and the abnormal pattern of expression of the
5HT2CR or altered edited 5HT2CR ratio in PWS suggests that a
compromised 5-HT signaling might contribute to pathogenesis of
the disease (Cavaille et al., 2000, 2002; Kishore and Stamm, 2006;
Kishore et al., 2010). This idea is supported by data in genetically
modiﬁed mice expressing only the fully edited 5HT2CR, which
mimics a PWS-like phenotype (Morabito et al., 2010). In addition,
many other snoRNAs are mapped to the Prader Willi locus such
as HBII-13, HBII-52, and HBII-85, and these may also be involved
in or be regulated by imprinting (Rogelj and Giese, 2004).
DYSREGULATED LONG NON-CODING RNAs IN
NEURODEGENERATION
Numerous brain-speciﬁc lncRNAs are alternatively spliced, devel-
opmentally regulated, and are physiologically responsive (Furuno
et al., 2006; Kapranov et al., 2007). lncRNAs that are derived
from the mammalian genome are both polyadenylated and non-
polyadenylated (Mattick andGagen,2001;Huang et al., 2012; Song
et al., 2012). Imprinting and antisense transcription of lncRNAs
that host genes for miRNAs and snoRNAs that are localized to
the nucleus of nervous tissue suggest that these lncRNAs may be
involved in gene regulation (Furuno et al.,2006). The transcription
patterns of lncRNAs are in complex intergenic, overlapping, and
antisense patterns relative to adjacent protein-coding genes (Satoh,
2012; Tran et al., 2012). Thus, it is possible that the lncRNAs reg-
ulate the expression of those genes. LncRNAs are involved in the
formation and function of cellular organelles that are regulated
transcriptionally and developmentally in a cell-speciﬁc manner
(Satoh, 2012; Tran et al., 2012). The functions of numerous lncR-
NAs are not known but studies suggest that they play an important
role in cell identifying the neuronal and glial cells in the CNS
(Mercer et al., 2010).
Patients with HD have widespread changes in their brain gene
regulatory networks (Ideker and Sharan, 2008). These changes
include non-protein coding RNAs and protein coding RNAs.
Seven lncRNAs in the human brain are speciﬁcally dysregu-
lated in HD (Johnson, 2012). New ﬁndings suggest that, besides
protein-coding genes, ncRNAs also contribute to neurodegener-
ative processes. Evidence for a role for ncRNAs in HD comes
from the genome-wide data where novel, non-coding targets
of RE1-silencing transcription factor (REST) were discovered
(Buckley et al., 2010; Johnson et al., 2010). A human accelerated
region 1 (HAR1) speciﬁcally is transcribed in the nervous system.
REST is targeted to the HAR1 locus that is recognized by spe-
ciﬁc DNA regulatory motifs and results in potent transcriptional
repression. Aberrant nuclear localization of the master transcrip-
tional repressor REST disrupts the gene regulatory networks in
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the neurons of HD patients. Notably, HAR1 levels are signif-
icantly lower in the striatum of HD patients compared with
unaffected individuals. Interestingly, many of these lncRNAs con-
tain genomic binding sites for the transcriptional repressor REST,
a key mediator of transcriptional changes in HD, including the
known REST target lncRNA,DGCR5. LncRNAs TUG1 (necessary
for retinal development), and NEAT1 (a structural component
of nuclear paraspeckles) are upregulated in HD caudate, while
the brain-speciﬁc tumor-suppressor MEG3 is downregulated in
HD (Johnson, 2012). Formation of epigenetic ribonucleopro-
tein complexes, including lncRNAs TUG1 and MEG3, regulates
gene expression. All together these ﬁndings suggest that changes
in lncRNA expression are widespread in HD, contributing to
altered epigenetic gene regulation in diseased neurons and likely
corresponding neurodegeneration. Thus, studying the regulation
of non-coding gene expression changes and lncRNA network
changes in HDmay provide a better understanding of and suggest
novel treatments for not only HD but also other neurodegen-
erative processes. For example, the lncRNA BACE 1 has been
directly implicated in upregulation of amyloid-beta 1–42 in AD
(Faghihi et al., 2008). Thus lncRNAs play an important role in
regulating gene expression for normal functioning of the nervous
system.
DYSREGULATED IMPRINTED NON-CODING RNAs IN
NEURODEGENERATION
Imprinted genes are known to play essential roles in both neu-
ral development and adult CNS functioning. Alterations in their
expression proﬁles are linked to a spectrum of complex neurode-
velopment and neuropsychiatric disorders (Costa, 2005; Davis
et al., 2005). These allele-selective genes exhibit preferential and
exquisite cell-speciﬁc patterns of expression within the brain and
are frequently processed from larger transcriptional units that
encompasses multiple tandem repeats of snoRNAs and miRNAs
(Sleutels et al., 2000; Costa, 2005; Davis et al., 2005; Lewis and
Reik, 2006). These imprinted loci usually generate a complex
spectrum of spliced and unspliced larger ncRNAs of unknown
function (Sleutels et al., 2000; Costa, 2005; Davis et al., 2005;
O’Neill, 2005; Furuno et al., 2006). Additional ncRNAs are associ-
ated with imprinted loci that include the production of antisense
RNAs to reciprocally imprinted neighboring protein-coding genes
(Sleutels et al., 2000; Davies et al., 2005). The role of imprinted
genes in regulating distinct brain signaling systems and in mediat-
ing brain–behavior relationships canbe deduced from spectrumof
neurological diseases causedbydisruptions in imprinted loci: PWS
andAngelman syndromes, autism, schizophrenia, attention deﬁcit
hyperactivity disorder, bipolar disorder, and Tourette’s syndrome
(Davies et al., 2004, 2005, 2006; Wang et al., 2004b).
DYSREGULATED TRANSFER AND RIBOSOMAL RNAs IN
NEURODEGENERATIVE DISEASE
Adenosine deaminase that act on RNA have the ability to
act in concert with ADATs to modify transfer RNAs (tRNAs)
to change codon recognition. Interestingly, a mutation in
the “editing” domain of a speciﬁc aminoacyl-tRNA synthetase
results in mischarged tRNAs, intracellular accumulation of
misfolded proteins in neurons, and induction of the endoplasmic
reticulum-mediated unfolded protein stress response with asso-
ciated neurodegeneration (Lee et al., 2006). tRNAs and rRNAs
are implicated in a broad array of neural developmental and
mature CNS functions. Not surprisingly, therefore, mutations
in these two classes of ncRNAs underlie a range of neurode-
velopment, neurodegenerative, and neuropsychiatric diseases.
Such examples include chronic progressive external ophthalmo-
plegia (CPEO), Kearn–Sayre syndrome (KSS: CPEO with retinal
degeneration), mitochondrial myopathy, encephalopathy, lac-
tic acidosis, and stroke (MELAS) syndrome that manifests in
mitochondrial encephalopathy with stroke-like syndromes and
migraine headaches, myoclonic epilepsy with ragged red ﬁbers
(MERRF) syndrome that results in myoclonus epilepsy, mito-
chondrial myopathy, cerebella ataxia (Dimauro, 2004; Dimauro
and Davidzon, 2005; Fattal et al., 2006), andmotor neuron disease
(Borthwick et al., 2006). Other tRNA-mediated neuropsychiatric
diseases include schizophrenia, psychosis, delirium, personality
disorders,major depressive disorders, and anxiety disorders (Fattal
et al., 2006). Besides tRNA-associated diseases, deregulated rRNA
is also implicated in RNA oxidation of vulnerable neurons in AD
(Honda et al., 2005).
DYSREGULATED RNA TRINUCLEOTIDE EXPANSIONS IN
NEURODEGENERATION
The expansion of trinucleotide repeats caused by RNA-mediated
mechanisms is associated with neurodegenerative diseases (Gallo
et al., 2005; Gatchel and Zoghbi, 2005). Dramatically expanded
(>200) CGG repeats in the 5′ UTR of the Fmr1 gene results
in fragile X syndrome. The related disease is also associated
with smaller (60–200) trinucleotide repeat expansion called frag-
ile X tremor/ataxia syndrome (FXTAS). FXTAS is associated with
tremor, cerebella ataxia, cognitive decline, peripheral neuropathy,
PD, autonomic dysfunction, proximal muscle weakness, multi-
system atrophy, and dementia (Hagerman et al., 2005; Van Esch,
2006). Myotonic dystrophy, another trinucleotide disorder, is pre-
dominantly a muscle disorder which exists in two neurological
forms: DM1 with mental retardation, memory, visuo-spatial, and
executive dysfunction, and DM2 with preferential executive dys-
function (D’Angelo and Bresolin, 2006). DM1 is associated with
CTG expansion within the 3′ UTR of the dystrophia myoton-
ica protein kinase (DMPK) gene, and DM2 is linked to CCTG
expansion in intron 1 of the zinc ﬁnger protein gene ZNF9 (Brook
et al., 1992; Fu et al., 1992; Mahadevan et al., 1992; Ranum et al.,
1998). These mutant RNAs orchestrate different forms of patho-
genesis depending on the degree and type of expanded repeat
length and their molecular interactions with the muscleblind-
like (MBNL) family of RNA-binding proteins (Jiang et al., 2004;
Pascual et al., 2006).
Several forms of spinocerebellar ataxia (SCA) are also impli-
cated in different RNA-mediated pathological mechanisms. SCA8
results from CTG expansion of the 3′ UTR of an untranslated
antisense RNA with partial overlap with the Kelch-like 1 (KLHL1)
gene (Koob et al., 1999; Nemes et al., 2000; Mutsuddi et al., 2004;
Gatchel and Zoghbi, 2005). Utilizing SCA8 as a modiﬁer screen,
four novel ncRNAs have been identiﬁed that show preferential
neuronal expression (Mutsuddi et al., 2004). SCA10 is mediated
by an unstable ATTCT repeat expansion in the 3′ end of a
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large intron of a gene of unknown function that may result in
transcriptional silencing or in a different RNA-associated toxic
mechanism (Matsuura et al., 2000). SCA12 is caused by CAG
expansion in the non-coding 5′ promoter or 5′ UTR of the
PPP2R2B gene, which encodes a brain-speciﬁc regulatory subunit
of protein phosphatase 2A (Holmes et al., 1999). All together these
ﬁndings suggest that, depending on where the expanded trinu-
cleotide repeat is localized, disease pathogenesis is likely mediated
by distinct trans-dominant RNA or alternatively by toxic gain of
function mechanisms (Holmes et al., 2003). Taken together, these
studies suggest that elucidating the lncRNA network is an impor-
tant step toward understanding neurodegeneration andmay reveal
new targets to treat neurodegenerative diseases.
SUMMARY
RNA is a carrier of information and plays a central role in reg-
ulating development. A variety of regulatory non-protein-coding
RNA molecules form complex multi-layered biological systems.
A gene regulatory network that allows normal functioning of
the CNS governs this complex system. A deregulated complex
gene regulatory network plays a signiﬁcant role in common neu-
rodegenerative diseases. Furthermore, the list of known ncRNAs
implicated in mammalian brain health and disease is growing.
RNA can alter the information in the genetic code without alter-
ing the hard-wiredDNA through splicing andRNA editing. ADAR
substrates involved in RNA editing mechanisms provide func-
tional complexity. RNA editing mediates the environmental cues
by transmitting information to the epigenome. This mechanism
connects the environment to the genome and plays important
roles in a broad range of processes, from evolution to learning
and memory. A to I RNA editing, besides altering protein func-
tion, also has the potential to alter splice site choice, miRNA target
diversity,miRNA processing, and perhaps chromatin architecture.
Furthermore, RNA editing alters RNA structure and thereby could
potentially impact the biological functions of multiple types of
ncRNAs. Therefore, RNA editing, RNA modiﬁcation, small and
long ncRNAs, and their complex regulatory network lead to a
unifying theme of RNA-mediated regulatory circuitry for normal
brain function.
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